These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 16827956)

  • 21. Interferon alpha-2b and ribavirin for patients with chronic hepatitis C and normal ALT.
    Mukherjee S
    Am J Gastroenterol; 2005 Mar; 100(3):727; author reply 727. PubMed ID: 15743377
    [No Abstract]   [Full Text] [Related]  

  • 22. Declining sustained virological response in hepatitis C.
    Batool U; Qureshi S
    J Coll Physicians Surg Pak; 2006 Mar; 16(3):187-91. PubMed ID: 16542597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response to combination therapy in hepatitis virus C genotype 2 and 3.
    Khan AA; Sarwar S
    J Coll Physicians Surg Pak; 2009 Aug; 19(8):473-7. PubMed ID: 19651007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
    Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
    J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
    Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
    N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon-alpha2a/ribaviran versus interferon-alpha2a alone for the retreatment of hepatitis C patients who relapse after a standard course of interferon.
    Chapman BA; Stace NH; Edgar CL; Bartlett SE; Frampton CM; Scahill SL; Jennings LC
    N Z Med J; 2001 Mar; 114(1128):103-4. PubMed ID: 11346153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic hepatitis C and normal ALT: considerations for treatment.
    Bacon BR
    Am J Gastroenterol; 2004 Sep; 99(9):1706-7. PubMed ID: 15330906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers.
    Blatt LM; Tong MJ; McHutchison JG; Russell J; Schmid P; Conrad A
    J Interferon Cytokine Res; 1998 Feb; 18(2):75-80. PubMed ID: 9506457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
    Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
    J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon alpha-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1.
    Brandão C; Barone A; Carrilho F; Silva A; Patelli M; Caramori C; Focaccia R; Pereira L; Pedroso M; Tatsch F; Pessoa M;
    J Viral Hepat; 2006 Aug; 13(8):552-9. PubMed ID: 16901286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial.
    Berg T; Kronenberger B; Hinrichsen H; Gerlach T; Buggisch P; Herrmann E; Spengler U; Goeser T; Nasser S; Wursthorn K; Pape GR; Hopf U; Zeuzem S
    Hepatology; 2003 Jun; 37(6):1359-67. PubMed ID: 12774015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discrepancy in virological and biochemistry response of patients with chronic hepatitis HCV positive on treatment with PEG-IFN plus ribavirin.
    Marino N; Blanc PL; Blè C; Pierotti P; Mazzotta F
    J Biol Regul Homeost Agents; 2003; 17(2):205-6. PubMed ID: 14518725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High rate of sustained response to consensus interferon plus ribavirin in chronic hepatitis C patients resistant to alpha-interferon and ribavirin: a pilot study.
    da Silva LC; Bassit L; Ono-Nita SK; Pinho JR; Nishiya A; Madruga CL; Carrilho FJ
    J Gastroenterol; 2002; 37(9):732-6. PubMed ID: 12375147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of pegylated interferon alpha 2b and ribavirin in chronic hepatitis C--a report from eastern India.
    Ray G; Pal S; Nayyar I; Dey S
    Trop Gastroenterol; 2007; 28(3):109-12. PubMed ID: 18383998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effects of treatment with pegylated interferon and ribavirin in children with chronic hepatitis C].
    Kowala-Piaskowska A; Figlerowicz M; Mozer-Lisewska I; Słuzewski W
    Przegl Epidemiol; 2005; 59(2):491-8. PubMed ID: 16190558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Re-evaluation of the serum alanine aminotransferase upper normal limit in chronic hepatitis C patients.
    Yagura M; Tanaka A; Kamitsukasa H; Otsuka H; Kanno S; Aoyama T
    Intern Med; 2010; 49(6):525-8. PubMed ID: 20228585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of hepatitis C patients with normal aminotransferases levels.
    Marcellin P; Martinot M; Boyer N; Lévy S
    Clin Liver Dis; 1999 Nov; 3(4):843-53. PubMed ID: 11291254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic hepatitis C viral infection in patients with normal serum alanine aminotransferases.
    Di Bisceglie AM
    Am J Med; 1999 Dec; 107(6B):53S-55S. PubMed ID: 10653458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.